NC
Nexthera Capital Portfolio holdings
AUM
$120M
This Quarter Return
+4.1%
1 Year Return
+20.18%
3 Year Return
+117.79%
5 Year Return
–
10 Year Return
–
AUM
$185M
AUM Growth
+$185M
(+26%)
Cap. Flow
+$34.5M
Cap. Flow
% of AUM
18.61%
Top 10 Holdings %
Top 10 Hldgs %
63.47%
Holding
49
New
15
Increased
7
Reduced
12
Closed
8
Top Buys
| 1 |
BioMarin Pharmaceuticals
BMRN
|
$9.16M |
| 2 |
IPXL
Impax Laboratories, Inc.
IPXL
|
$9.02M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$8.38M |
| 4 |
Aclaris Therapeutics
ACRS
|
$6.2M |
| 5 |
FLXN
Flexion Therapeutics, Inc.
FLXN
|
$4.66M |
Top Sells
| 1 |
Pfizer
PFE
|
$14.6M |
| 2 |
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
|
$3.02M |
| 3 |
CELG
Celgene Corp
CELG
|
$2.71M |
| 4 |
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
|
$2.41M |
| 5 |
TVRD
Tvardi Therapeutics, Inc. Common Stock
TVRD
|
$2.21M |
Sector Composition
| 1 | Healthcare | 87.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SHPG
1
DELISTED
Shire pic
SHPG
| $16.8M | 7.31% | 101,500 -2,500 | -2% | -$413K |
|
|
ALXN
2
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $14.6M | 6.36% | 120,000 +33,500 | +39% | +$4.08M |
|
3
GSK
GSK
$79.9B
| $13.9M | 6.05% | 322,000 +5,500 | +2% | +$237K |
|
|
CELG
4
DELISTED
Celgene Corp
CELG
| $12.9M | 5.61% | 99,110 -20,890 | -17% | -$2.71M |
|
|
5
Pfizer
PFE
$141B
| $11.8M | 5.12% | 350,030 -435,021 | -55% | -$14.6M |
|
|
KITE
6
DELISTED
Kite Pharma, Inc.
KITE
| $10.4M | 4.52% | 100,000 -5,000 | -5% | -$518K |
|
|
NDRM
7
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
| $9.78M | 4.26% | 327,240 +39,240 | +14% | +$1.17M |
|
|
GBT
8
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $9.3M | 4.05% | 340,100 +135,600 | +66% | +$3.71M |
|
|
9
Aclaris Therapeutics
ACRS
$209M
| $9.22M | 4.02% | 340,000 +228,500 | +205% | +$6.2M |
|
|
10
BioMarin Pharmaceuticals
BMRN
$11.2B
| $9.16M | 3.99% | +100,800 | New | +$9.16M |
|
|
IPXL
11
DELISTED
Impax Laboratories, Inc.
IPXL
| $9.02M | 3.93% | +560,400 | New | +$9.02M |
|
|
12
Alnylam Pharmaceuticals
ALNY
$58.5B
| $8.38M | 3.65% | +105,000 | New | +$8.38M |
|
13
Vanda Pharmaceuticals
VNDA
$279M
| $7.53M | 3.28% | 462,200 -50,000 | -10% | -$815K |
|
14
Minerva Neurosciences
NERV
$16.5M
| $5.09M | 2.22% | 575,000 -182,200 | -24% | -$1.61M |
|
|
FLXN
15
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $4.66M | 2.03% | +230,500 | New | +$4.66M |
|
|
DOVA
16
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
| $4.42M | 1.92% | +198,059 | New | +$4.42M |
|
|
DERM
17
DELISTED
Dermira, Inc.
DERM
| $3.51M | 1.53% | +120,600 | New | +$3.51M |
|
18
Insmed
INSM
$28.8B
| $2.75M | 1.2% | +160,000 | New | +$2.75M |
|
|
RXDX
19
DELISTED
Ignyta, Inc.
RXDX
| $2.59M | 1.13% | 250,000 -85,000 | -25% | -$880K |
|
|
STDY
20
DELISTED
SteadyMed Ltd
STDY
| $2.27M | 0.99% | 360,626 +355,227 | +6,579% | +$2.24M |
|
21
Abeona Therapeutics
ABEO
$350M
| $2.27M | 0.99% | 354,000 -140,064 | -28% | -$897K |
|
|
RARX
22
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $1.91M | 0.83% | +102,054 | New | +$1.91M |
|
23
Kamada
KMDA
$398M
| $1.81M | 0.79% | +300,781 | New | +$1.81M |
|
|
KDNY
24
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $1.77M | 0.77% | +155,000 | New | +$1.77M |
|
|
ADXS
25
DELISTED
Advaxis, Inc.
ADXS
| $1.64M | 0.71% | 252,000 +155,200 | +160% | +$1.01M |
|